• W. Brück
Part of the Topics in Neuroscience book series (TOPNEURO)


Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). The pathological hallmarks are the destruction of myelin, the death of oligodendrocytes, and the loss of axons [1,2]. These changes occur against an inflammatory background which consists of inflammatory infiltrates composed of macrophages, microglia, and T and B cells, and is accompanied by an intense reaction of astrocytes leading to the typical glial scar formation of the chronic MS lesion. The lesions are scattered throughout the CNS, with a predilection for the optic nerves, brainstem, spinal cord, cerebellum, and periventricular white matter. Despite years of classical histopathological study and more recent intensive use of magnetic resonance technology, the MS lesion is incompletely understood [3]. How it is initiated, how it changes over time, and how it correlates with clinical symptoms or clinical course are all largely unknown. Therefore, it is essential that the evolution of the MS lesion is better understood and its clinical and paraclinical correlates defined.


Multiple Sclerosis Multiple Sclerosis Patient Multiple Sclerosis Lesion Axonal Damage Primary Progressive Multiple Sclerosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Prineas JW (1985) The neuropathology of multiple sclerosis. In: Koetsier JC (ed) Demyelinating diseases. Elsevier Science, Amsterdam, pp 213–257Google Scholar
  2. 2.
    Lassmann H (1998) Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H et al (eds) McAlpine’s multiple mclerosis. Churchill Livingstone, London, pp 323–358Google Scholar
  3. 3.
    Lucchinetti C, Brück W, Noseworthy JH (2001) Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging and treatment. Curr Opin Neurol 14:259–269PubMedCrossRefGoogle Scholar
  4. 4.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907–911PubMedGoogle Scholar
  5. 5.
    Thompson AJ, Montalban X, Barkhof F et al (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831–835PubMedCrossRefGoogle Scholar
  6. 6.
    Thompson AJ, Polman CH, Miller DH et al (1997) Primary progressive multiple sclerosis. Brain 120:1085–1096PubMedCrossRefGoogle Scholar
  7. 7.
    Lassmann H, Raine CS, Antel J, Prineas JW (1998) Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86:213–217PubMedCrossRefGoogle Scholar
  8. 8.
    Traugott U, Reinherz EL, Raine CS (1983) Multiple sclerosis. Distribution of T cells, T cell subsets and la-positive macrophages in lesions of different ages. J Neuroimmunol 4:201–221Google Scholar
  9. 9.
    Brück W, Porada P, Poser S et al (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38:788–796PubMedCrossRefGoogle Scholar
  10. 10.
    Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117:759–765PubMedCrossRefGoogle Scholar
  11. 11.
    Zettl UK, Kuhlmann T, Brück W (1998) Bcl-2 expressing T lymphocytes in multiple sclerosis lesions. Neuropathol Appl Neurobiol 24:202–208PubMedCrossRefGoogle Scholar
  12. 12.
    Durán I, Martinez-Cáceres EM, Rio J et al (1999) Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122:2297–2307Google Scholar
  13. 13.
    Bashir K, Whitaker JN (1999) Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 53:765–771PubMedGoogle Scholar
  14. 14.
    Lucchinetti C, Brück W, Parisi J et al (1999) A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 122:2279–2295PubMedCrossRefGoogle Scholar
  15. 15.
    Kuhlmann T, Lucchinetti C, Zettl UK et al (1999) Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. Glia 28:34–39PubMedCrossRefGoogle Scholar
  16. 16.
    Lucchinetti C, Brück W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717PubMedCrossRefGoogle Scholar
  17. 17.
    Lassmann H, Brück W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7:115–121PubMedCrossRefGoogle Scholar
  18. 18.
    Kornek B, Lassmann H (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9:651–656Google Scholar
  19. 19.
    Trapp BD, Ransohoff R, Rudick R (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12:295–302PubMedCrossRefGoogle Scholar
  20. 20.
    Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393–399PubMedCrossRefGoogle Scholar
  21. 21.
    Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285PubMedCrossRefGoogle Scholar
  22. 22.
    Bitsch A, Schuchardt J, Bunkowski S et al (2000) Axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123:1174–1183Google Scholar
  23. 23.
    Sadatipour BT, Greer JM, Pender MP (1998) Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 44:980–983PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2002

Authors and Affiliations

  • W. Brück

There are no affiliations available

Personalised recommendations